Associations between the use of aspirin or other antiplatelet drugs and all-cause mortality among patients with COVID-19: A meta-analysis.

Su, Wanting; Miao, He; Guo, Zhaotian; Chen, Qianhui; Huang, Tao; Ding, Renyu

Su, Wanting; Miao, He; Guo, Zhaotian; Chen, Qianhui; Huang, Tao; Ding, Renyu.

Afiliação

Su W; Department of Critical Care Medicine, The First Hospital of China Medical University, Shenyang, Liaoning Province, China.
Miao H; Department of Critical Care Medicine, The First Hospital of China Medical University, Shenyang, Liaoning Province, China.
Guo Z; Department of Critical Care Medicine, The First Hospital of China Medical University, Shenyang, Liaoning Province, China.
Chen Q; Department of Critical Care Medicine, The First Hospital of China Medical University, Shenyang, Liaoning Province, China.
Huang T; Department of Epidemiology & Biostatistics, School of Public Health, Peking University, Beijing, China.
Ding R; Key Laboratory of Molecular Cardiovascular Sciences (Peking University), Ministry of Education, Beijing, China.

Front Pharmacol ; 13: 989903, 2022.

Article em En | MEDLINE | ID: mdl-36278186

Palavras-chave

COVID-19; antiplatelet drug; aspirin; meta-analysis; mortality

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google